학술논문
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
Document Type
Article
Author
Molina, Jean-Michel; Squires, Kathleen; Sax, Paul E; Cahn, Pedro; Lombaard, Johan; DeJesus, Edwin; Lai, Ming-Tain; Xu, Xia; Rodgers, Anthony; Lupinacci, Lisa; Kumar, Sushma; Sklar, Peter; Nguyen, Bach-Yen; Hanna, George J; Hwang, Carey; Martins, Marcelo; Cahn, Pedro Enrique; Lopardo, Gustavo D.; Porteiro, Norma; Bloch, Mark Theo; Baker, David Alfred; Roth, Norman; Moore, Richard James; Finlayson, Robert James; McMahon, James; Rieger, Armin; Zoufaly, Alexander; Hartl, Sylvia; Zangerle, Robert; Smaill, Fiona; Walmsley, Sharon L.; Conway, Brian; Rachlis, Anita; Smith, Graham H.R.; Perez, Carlos; Afani, Alejandro; Campos Barker, Maria Isabel E.; Chahin, Carolina Eugenia; Wolff Reyes, Marcelo; Gerstoft, Jan; Weis, Nina; Laursen, Alex Lund; Molina, Jean-Michel; Yazdanpanah, Yazdan; Cotte, Laurent; Raffi, Francois; Morlat, Philippe; Girard, Pierre-Marie; Katlama, Christine; Rockstroh, Juergen K.; Arasteh, Keikawus; Esser, Stefan; Stoehr, Albrecht; Stellbrink, Hans-Juergen; Stoll, Matthias; Schuermann, Dirk; Faetkenheuer, Gerd; Bogner, Johannes; Lutz, Thomas; Baumgarten, Axel; Jaeger, Hans; Gori, Andrea; Coltan, Gabriel; Constandis, Felicia; Erscoiu, Simona Manuela; Prisacariu, Liviu-Jany; Rugina, Sorin; Streinu-Cercel, Adrian; Pokrovsky, Vadim Valentinovich; Zakharova, Natalia V.; Shuldyakov, Andrey Anatolyevich; Ryamova, Elena Pavlovna; Kulagin, Valeriy Viktorovich; Tsybakova, Olga Aleksandrovna; Orlova-Morozova, Elena; Nagimova, Firaya; Voronin, Evgeniy; Shimonova, Tatyana Evgenyevna; Kozyrev, Oleg Anatolyevich; Orrell, Catherine; Lombaard, Johannes Jurgens; Botes, Margaretha Elizabeth; Portilla, Joaquin; Gatell, Josep Maria; Perez, Maria Jesus; Arribas, Jose Ramon; Negredo, Eugenia; Podzamczer, Daniel; Pulido, Federico; Troya, Jesus; De los Santos, Ignacio; Berenguer, Juan; Williams, Ian G.; Johnson, Margaret A.; Schembri, Gabriel; Clarke, Amanda; Gompels, Mark; Fox, Julie Meriel; Taylor, Steven John; Kegg, Stephen; Hagins, Debbie P.; Osiyemi, Olayemi O.; Prelutsky, David James; Ramgopal, Moti N.; Dretler, Robin; DeJesus, Edwin; Sloan, Louis; Lewis, Stanley T.; Clay, Patrick G.; Bellos, Nicholaos C.; Thompson, Melanie A.; Montero, Jose; McDonald, Cheryl K.; Creticos, Catherine; Shamblaw, David; Terrelonge, Antonio E.; Valdes, Martin; Tashima, Karen T.; Robbins, William J.; Felizarta, Franco Antonio; Elion, Richard A.; Slim, Jihad; Lalezari, Jacob Paul; Lalla-Reddy, Sujata N.; Ruane, Peter Jerome; Mills, Anthony; Cade, Jerry L.; Campo, Rafael E.; Dietz, Craig A.; Blick, Gary; Mayer, Cynthia; Rondon, Juan Carlos; Cook, Paul P.; Daar, Eric; Kumar, Princy N.; Swindells, Susan; Castro, Jose Guillermo; Morales-Ramirez, Javier O.; Santiago, Lizette; Santana-Bagur, Jorge L.
Source
The Lancet HIV; May 2018, Vol. 5 Issue: 5 pe211-e220, 10p
Subject
Language
ISSN
24054704; 23523018
Abstract
Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with a pharmacokinetic profile supporting once-daily dosing, and potent in-vitro activity against the most common NNRTI-resistant HIV-1 variants. We compared doravirine with ritonavir-boosted darunavir, when both were given with two nucleoside reverse transcriptase inhibitors (NRTIs), in adults with previously untreated HIV-1 infection.